Literature DB >> 11964888

Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy.

M I Restrepo1, J H Jorgensen, E M Mortensen, A Anzueto.   

Abstract

Severe community-acquired pneumonia is a clinical diagnosis with a significant impact on healthcare management around the world, with the highest morbidity and mortality of all of the forms of community-acquired pneumonia. Patients with severe pneumonia usually require intensive care unit management, including vasopressors or mechanical ventilation. Early clinical suspicion and prompt empiric antimicrobial therapies are mandatory in patients with severe pneumonia. A number of recent studies and guidelines addressing these issues have been published, and they will be reviewed in this article.

Entities:  

Mesh:

Year:  2001        PMID: 11964888     DOI: 10.1097/00001432-200112000-00007

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  12 in total

Review 1.  Defining severe pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Clin Chest Med       Date:  2011-07-12       Impact factor: 2.878

2.  High prevalence of respiratory viral infections in patients hospitalized in an intensive care unit for acute respiratory infections as detected by nucleic acid-based assays.

Authors:  Jérôme Legoff; Emmanuel Guérot; Angélique Ndjoyi-Mbiguino; Mathieu Matta; Ali Si-Mohamed; Laurent Gutmann; Jean-Yves Fagon; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 3.  Defining and predicting severe community-acquired pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Curr Opin Infect Dis       Date:  2010-04       Impact factor: 4.915

4.  Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.

Authors:  Samuel M Brown; Barbara E Jones; Al R Jephson; Nathan C Dean
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

Review 5.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Antimicrobial susceptibility and genetic characteristics of Streptococcus pneumoniae isolates indicating possible nosocomial transmission routes in a community hospital in Japan.

Authors:  Liang Qin; Hironori Masaki; Kiwao Watanabe; Akitsugu Furumoto; Hiroshi Watanabe
Journal:  J Clin Microbiol       Date:  2007-09-12       Impact factor: 5.948

7.  Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice.

Authors:  J Barth; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

8.  Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

Authors:  Alejandro Rodriguez; Thiago Lisboa; Stijn Blot; Ignacio Martin-Loeches; Jorge Solé-Violan; Diego De Mendoza; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

9.  Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae.

Authors:  G M Vail; Y J Xie; D J Haney; C J Barnes
Journal:  Infection       Date:  2009-01-23       Impact factor: 3.553

10.  Outcomes and prognostic factors for severe community-acquired pneumonia that requires mechanical ventilation.

Authors:  Jin Hwa Lee; Yon Ju Ryu; Eun Mi Chun; Jung Hyun Chang
Journal:  Korean J Intern Med       Date:  2007-09       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.